European Consumers Seeking Health and Pharmaceutical Information

Manhattan Research, LLCEuropean consumers have been a long-neglected piece of the strategic puzzle for most marketers at health and pharmaceutical companies. Yet signs increasingly point to the degree to which European consumers are, in fact, researching health information and treatment options, and ultimately taking action as a result of those information searches.

Consumers in Europe are renowned for being extremely technologically advanced in terms of online activities and technology and device ownership. But due to the lack of direct-to-consumer advertising for pharmaceuticals, many pharmaceutical companies have assumed that consumers were somewhat passive participants in the patientphysician relationship. However, according to a recent study by Manhattan Research, European consumers are more likely to have researched health information online than they are to have participated in online dating, online gaming or even online bill pay.

Given the propensity of European consumers to use the Internet for health and pharmaceutical information, Manhattan Research has outlined three key trends in the market that every health and pharmaceutical market must be aware of and plan for today.

European Consumers Are Researching Health and Pharmaceutical Information to Make Decisions
Although consumers in Europe are less likely than consumers in the United States to research pharmaceutical information online, in part due to the lack of pharmaceutical advertising in Europe, fully one-third of online consumers in Europe research pharmaceuticals online today. Such information is clearly having an impact; nearly 80% of these consumers go on to take some sort of action as a result of their information searches - more on that in trend number three. The numbers illustrate a market that has embraced the Internet as not only a source of content and entertainment, but as a robust resource to evaluate health and wellness, symptoms, treatment options, and specifically what pharmaceuticals may or may not be available in the market today. The market has spoken and is saying loudly and clearly that the Internet now rivals "traditional" mass media as a health information resource.

Furthermore, in the absence of direct-to-consumer advertising, or local product.com destinations for European consumers, consumers are actually going to the corporate sites of pharmaceutical companies for health and pharmaceutical information. In fact, an estimated 21 million consumers report visiting corporate sites in the past 12 months across the 10 countries surveyed in the research. Pfizer, Bayer and GSK are the top three corporate sites visited by consumers for information, with such visitors reporting to access these sites for health and treatment information specifically. Companies would be wise to heed this trend, and provide patient-friendly disease education content in the local language on the local portal for the company - a feature that would be a benefit to patients and physicians alike. Perhaps of no surprise is that there is also a segment of consumers in Europe that have taken the initiative to "cross the pond" to the United Status content sites for pharmaceutical information - where branded websites provide detailed information about branded products. Of course, the only catch is that these are typically only available in English - suitable for the UK resident but a challenge for other markets.

Plus it is not just pharmaceutical information European consumers are after today. Consumers are also researching a wide range of diseases online. As evidenced by the chart below, in addition to conditions with high incidence rates (such as allergies), consumers are actively seeking information about depression and targeted topics such as cancer, which has a relatively low population of patients compared to the population seeking information online - speaking to the power of those beyond the patient to access information.

For further information and Cybercitizen® Health Europe White Paper download, please visit:
www.manhattanresearch.com/CCHEU.aspx

About Manhattan Research
In addition to Cybercitizen® Health Europe, Manhattan Research conducts five annual research studies among consumers and physicians in the United States and in Europe. These studies include Cybercitizen® Health US, Taking the Pulse® Europe, Taking the Pulse® US, ePharma Physician®, and ePharma Consumer®. Each study serves a unique purpose and focuses on specific aspects of information technology adoption. Broad consumer and physician research is complemented by targeted analysis among more than 50 consumer therapeutic segments and 25 physician specialist segments. For further information, please visit www.manhattanresearch.com

Most Popular Now

Stepping Hill Hospital Announced as SPAR…

Stepping Hill Hospital, part of Stockport NHS Foundation Trust, has replaced its bedside units with state-of-the art devices running a full range of information, engagement, communications and productivity apps, to...

DMEA 2025: Digital Health Worldwide in B…

8 - 10 April 2025, Berlin, Germany. From the AI Act, to the potential of the European Health Data Space, to the power of patient data in Scandinavia - DMEA 2025...

New System for the Early Detection of Au…

A team from the Human-Tech Institute-Universitat Politècnica de València has developed a new system for the early detection of Autism Spectrum Disorder (ASD) using virtual reality and artificial intelligence. The...

Is AI in Medicine Playing Fair?

As artificial intelligence (AI) rapidly integrates into health care, a new study by researchers at the Icahn School of Medicine at Mount Sinai reveals that all generative AI models may...

Generative AI's Diagnostic Capabili…

The use of generative AI for diagnostics has attracted attention in the medical field and many research papers have been published on this topic. However, because the evaluation criteria were...

Diagnoses and Treatment Recommendations …

A new study led by Prof. Dan Zeltzer, a digital health expert from the Berglas School of Economics at Tel Aviv University, compared the quality of diagnostic and treatment recommendations...

AI Tool can Track Effectiveness of Multi…

A new artificial intelligence (AI) tool that can help interpret and assess how well treatments are working for patients with multiple sclerosis (MS) has been developed by UCL researchers. AI uses...

Surrey and Sussex Healthcare NHS Trust g…

Surrey and Sussex Healthcare NHS Trust has marked an important milestone in connecting busy radiologists across large parts of South East England, following the successful go live of Sectra's enterprise...

DMEA 2025 Ends with Record Attendance an…

8 - 10 April 2025, Berlin, Germany. DMEA 2025 came to a successful close with record attendance and an impressive program. 20,500 participants attended Europe's leading digital health event over the...

Dr Jason Broch Joins the Highland Market…

The Highland Marketing advisory board has welcomed a new member - Dr Jason Broch, a GP and director with a strong track record in the NHS and IT-enabled transformation. Dr Broch...

AI-Driven Smart Devices to Transform Hea…

AI-powered, internet-connected medical devices have the potential to revolutionise healthcare by enabling early disease detection, real-time patient monitoring, and personalised treatments, a new study suggests. They are already saving lives...

Multi-Resistance in Bacteria Predicted b…

An AI model trained on large amounts of genetic data can predict whether bacteria will become antibiotic-resistant. The new study shows that antibiotic resistance is more easily transmitted between genetically...